This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stock Futures Rising Ahead of U.S. Home Sales Report

NEW YORK ( TheStreet) -- Stock futures were eyeing a firm start to the week on expectations U.S. home contract signings improved in March, a positive sign for housing demand and momentum for the economic recovery.

Futures for the S&P 500 were up 5 points, or 4.36 points above fair value, to 1,581.5.

Markets also appeared buoyed by indications central banks around the world will continue implementing measures to stimulate their respective economies. The U.S. Federal Reserve is scheduled to make an announcement following its two-day policy meeting that ends on Wednesday while the European Central Bank is expected to do the same on Thursday.

"The recent data flow has been weaker in both America and the Eurozone but stock markets have remained resilient," Mansoor Mohi-uddin, head of foreign exchange strategy at UBS in Singapore, said in an investor note Monday. "The Federal Open Market Committee looks set to continue with its third round of quantitative easing. The ECB's Governing Council is also likely to cut its benchmark refinance rate by 25bps to 0.50% according to UBS Economics."

The National Association of Realtors is expected to report at 10 a.m. EDT Monday that its pending home sales index indicated that contract signings rose 1% in March after falling 0.4% in February.

The Bureau of Economic Analysis reported personal spending ticked up 0.2% last month after increasing 0.7% the previous month, and that personal income rose 0.2% in March after gaining 1.1% in February. Personal spending was forecast to be unchanged and personal income was seen rising 0.4% according to a survey of economists by Thomson Reuters.

Conceptus (CPTS) was soaring 20% to $31.08 in premarket trading. The contraceptive devices maker is being acquired by Germany's Bayer for $1.1 billion, or $31 a share in cash, a 19.7% premium over the stock's closing price on Friday.

Valeant Pharmaceuticals International (VRX - Get Report) was adding 2.52% to $75 and Actavis Inc. (ACT) was popping 5.15% to $106.14 amid reports that their merger talks have been put on hold over disagreements on the terms of the deal.

Auxilium Pharmaceuticals (AUXL) shares were down 2% to $15.69 after the company on Monday bought privately held Actient Holdings, a marketer of urology products, for $585 million in cash plus Auxilium stock contingencies and warrants.

Futures for the Dow Jones Industrial Average were rising 46 points, or 44.45 points above fair value, to 14,695. Futures for the Nasdaq were up 10.75 points, or 7.6 points above fair value, to 2,841.25.

The DAX in Germany was up 0.23% and the FTSE 100 in the UK was down 0.05%.

The benchmark 10-year Treasury was down 2/32, raising the yield to 1.674%. The dollar was down 0.37% to $82.20 according to the U.S. dollar index.

June crude oil futures were rising 42 cents to $93.42 and June gold futures were gaining $18.70 to $1,472.30 an ounce.

Written by Andrea Tse in New York

>To contact the writer of this article, click here: Andrea Tse.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACT $0.00 0.00%
AUXL $36.47 -0.16%
VRX $33.36 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs